-
2025-521394-13-00
1
"Relapsed/refractory Acute Myeloid Leukemia or relapsed/refra"
-
2025-523396-38-00
9
"Relapse or refractory (r/r) acute myeloid leukaemia (AML) an"
-
2025-523544-12-00
5
"Myelodysplastic neoplasms/syndromes (MDS)"
-
2024-519537-29-00
1
2026-03-13
"Acute Myeloid Leukemia and Myelodysplastic Syndrome"
-
2025-521299-76-00
7
2025-12-18
"Relapsed or refractory acute leukaemia or Myelodysplastic Sy"
-
2025-521673-14-00
4
2025-12-03
"Relapsed / Refractory Metastatic or Advanced Solid Tumors"
-
2022-500609-42-00
4
2023-02-24
"Anemia Due to Lower-Risk Myelodysplastic Syndromes"
-
2023-506145-38-00
3
2021-05-11
"Treatment of participants with MF, MDS, ET, or MDS/MPN"
-
2025-521372-62-00
4
2026-01-29
"Acute Myeloid Leukemia (AML), Myleodyplastic Neoplasm/Acute "
-
2023-507879-21-00
4
2026-01-19
"AML and MDS undergoing allogeneic Transplantation"
-
2024-512503-39-00
6
2025-12-19
"Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia "
-
2024-519779-24-00
4
2025-11-25
"VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMA"
-
2024-519928-24-00
4
2025-08-21
"Myelodysplastic Syndrome"
-
2024-515098-93-00
5
2025-07-22
"Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leuk"
-
2024-517247-31-00
5
2025-07-07
"Newly Diagnosed Higher Risk Myelodysplastic Syndrome"
-
2024-514341-10-00
1
2025-05-27
"Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or"
-
2024-519498-20-00
9
2025-05-13
"Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Sy"
-
2023-510155-37-00
5
2025-05-08
"Hypomethylating agent (HMA) naive myelodysplastic syndromes
"
-
2024-516009-22-00
5
2025-04-30
"myelodysplastic neoplasms/syndromes (MDS)"
-
2024-513199-16-00
1
2025-02-04
"Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or"
-
2024-515737-14-00
3
2024-10-07
"Acute leukemia and myelodysplastic syndromes"
-
2023-504555-27-00
5
2023-11-28
"Myelodysplastic syndrome (MDS)"
-
2023-505259-39-00
7
2023-03-02
"Acute Myeloid Leukemia (AML)"
-
2023-506945-42-00
1
2022-01-21
"Acute myeloid leukaemia"